Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of a Dengue Virus DNA Vaccine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Available to participate for the duration of the study (approximately 12 months)~* Completion and review of knowledge assement quiz~Exclusion Criteria:~* Pregnant (by history or as ascertained by pregnancy test) or lactating female~* Female who intends to become pregnant during the study~* Plan to have elective surgery during the study period~* HIV infection~* Known immunodeficiency or currently receiving immunosuppressive therapy (inhaled and topical steroids are allowed)~* History of splenectomy~* Administration of a vaccine not foreseen by the study protocol during the period starting 30 days before each dose of vaccine and ending 30 days after vaccination~* Evidence of active (acute or chronic) hepatitis B or C infection~* Autoimmune diseaseor subjects who describe a first-degree relative with clearly documented autoimmune disease~* Acute or chronic, clinically significant cardiac, pulmonary, hepatic, or renal abnormality, as determined by physical examination or basic laboratory screening~* Clinical or laboratory evidence of significant anemia~* History of flavivirus infection or previous receipt of flavivirus vaccine~* Positive serology for flaviviruses (all four dengue virus serotypes, Japanese encephalitis, Yellow fever virus, and West Nile virus), HIV-1, Hepatitis B surface antigen, or anti-hepatitis C virus antibodies prior to enrollment~* Use of any investigational or non-registered drug or vaccine other than the study vaccine within 60 days preceding the first dose of study vaccine, or planned use during the study period.~* Previous history of allergic or anaphylactic reaction to any vaccine~* Planned travel to areas with endemic dengue during the study period~* Any other significant finding which, in the opinion of the investigator, would increase the risk of having an adverse outcome from participating in this protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- 1.0 mg of D1ME100 vaccine (Type: EXPERIMENTAL): 1.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months
- 5.0 mg of D1ME100 vaccine (Type: EXPERIMENTAL): 5.0 mg dose of DME100 vaccine delivered by Biojector IM injections at 0, 1 and 5 months

Based on this trial design, predict the completion outcome and termination type (if applicable).